Immunochemical staining of MT2-MMP correlates positively to angiogenesis of human esophageal cancer

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4363-4368

  Chen, Lujun ^a   Di, Dongmei ^a   Lou, Guanghua ^a   Zheng, Lu ^a   Tan, Yan ^a   Zhang, Xiaoying ^a   Xu, Ning ^b  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Esophageal cancer; Intratumoral angiogenesis; MT2 MMP

Indexed keywords

MATRIX METALLOPROTEINASE 15;

ADULT; AGE; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; ESOPHAGUS CANCER; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 15; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

EID: 78650244557     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003.
2. Stoner GD and Gupta A: Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22: 1737-1746, 2001.
3. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL and Roth JA: Treatment outcomes of resected esophageal cancer. Ann Surg 236: 376-384; discussion 384-375, 2002.
4. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H and Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23: 4330-4337, 2005.
5. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
6. Brinckerhoff CE and Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3: 207-214, 2002.
7. Kerkela E, Ala-Aho R, Jeskanen L, Rechardt O, Grenman R, Shapiro SD, Kahari VM and Saarialho-Kere U: Expression of human macrophage metalloelastase (MMP-12) by tumor cells in skin cancer. J Invest Dermatol 114: 1113-1119, 2000.
8. Roy R, Yang J and Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27: 5287-5297, 2009.
9. Takino T, Watanabe Y, Matsui M, Miyamori H, Kudo T, Seiki M and Sato H: Membrane-type 1 matrix metalloproteinase modulates focal adhesion stability and cell migration. Exp Cell Res 312: 1381-1389, 2006.
10. Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD and Overall CM: Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem 276: 47402-47410, 2001.
11. Abraham R, Schafer J, Rothe M, Bange J, Knyazev P and Ullrich A: Identification of MMP-15 as an anti-apoptotic factor in cancer cells. J Biol Chem 280: 34123-34132, 2005.
12. Greene F L, Page DL, and Fleming ID, Fritz A, Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002.
13. Hammes LS, Tekmal RR Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjanen KJ and Cunha-Filho JS: Up-regulation of VEGF, C-FMS and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 110: 445-451, 2008.
14. Chen L, Luo G, Tan Y, Wei J, Wu C, Zheng L, Zhang X and Xu N: Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochem 112: 233-239, 2010.
15. Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9: 541-573, 1993.
16. Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M and Imai K: Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59: 3313-3316, 1999.
17. Gu ZD, Li JY, Li M, Gu J, Shi XT, Ke Y and Chen KN: Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 100: 1835-1843, 2005.
18. Yamashita K, Mori M, Shiraishi T, Shibuta K and Sugimachi K: Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 6: 1169-1174, 2000.
19. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
20. Hotary K, Allen E, Punturieri A, Yana I and Weiss SJ: Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 149: 1309-1323, 2000.
21. Lafleur MA, Handsley MM, Knauper V, Murphy G and Edwards DR: Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 115: 3427-3438, 2002.
22. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM and Noel A: MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 16: 555-564, 2002.
23. Sounni NE, Roghi C, Chabottaux V, Janssen M, Munaut C, Maquoi E, Galvez BG, Gilles C, Frankenne F, Murphy G, Foidart JM and Noel A: Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 279: 13564-13574, 2004.
24. Plaisier M, Kapiteijn K, Koolwijk P, Fijten C, Hanemaaijer R, Grimbergen JM, Mulder-Stapel A, Quax PH, Heimerhorst FM and van Hinsbergh VW: Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. J Clin Endocrinol Metab 89: 5828-5836, 2004.
25. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M and Okada Y: Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 57: 2055-2060, 1997.
26. Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P and Foidart JM: High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 65: 209-213, 1996.
27. Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Trope CG, Kopolovic J and Reich R: Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 115: 517-524, 2001. (Pubitemid 32275943)
28. Asano T, Tada M, Cheng S, Takemoto N, Kuramae T, Abe M, Takahashi O, Miyamoto M, Hamada J, Moriuchi T and Kondo S: Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res 146: 32-42, 2008.
29. Lyall M S, Dundas SR, Curran S and Murray GI: Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 12: 1184-1191, 2006.
30. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26: 2707-2716, 2008.
31. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A Wind P, Zinzindohoue F, Bruneval P, Cugnenc P H, Trajanoski Z, Fridman W H, and Pages F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006.